pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
GLP-1 receptor · news · pharmadog
← back to GLP-1 receptor
News · GLP-1 receptor
471
stories
2d
STAT+: Big drugmakers tell House committee they will halt clinical trials at some hospitals in China
stat
3d
STAT+: Pharmalittle: We’re reading about a Merck AI deal, China and the pharma supply chain, and more
stat
3d
Sanders’ ‘Medicare for All’ plan accrues more liberal and moderate support in Congress
stat
3d
STAT+: NIH to move last group of its research chimps to a sanctuary
stat
4d
‘Selling and marketing snake oil’: The debate over compounded GLP-1s
biopharma dive
4d
STAT+: Pharmalittle: We’re reading about Overton FDA nomination being yanked, a Merck setback, and more
stat
4d
Summit’s rejection, Isomorphic’s record $5B raise, obesity and Alzheimer’s in the spotlight
biospace
5d
STAT+: Pharmalittle: We’re reading about a Roche breast cancer pill, obesity drugs in children, and more
stat
5d
Lilly pens another deal, inking up to $5.9B oncology pact with Stipple
biospace
5d
STAT+: FDA approves new breast cancer drug, providing new option for some patients, boost for Roche
stat
6d
STAT+: Newer GLP-1 drugs to combat obesity may be the next global battleground over access to medicines, expert warns
stat
6d
Lilly’s early-stage M&A quest finds $1.5B deal for Calytrix’s blood cancer work
biospace
6d
Novo’s CagriSema drives more than 20% weight loss at lower doses
biospace
6d
Lilly's 14th acquisition of the year is a little-known blood cancer biotech
endpoints
6d
ObesityWeek 2026: Wave outlines case for body composition–based trial design
biospace
6d
STAT+: Pharmalittle: We’re reading about GLP-1 use, Covid-19 vaccine investment returns, and more
stat
6d
Lilly secures another myelofibrosis option via $1.5B deal for JPM-founded Calytrix
fiercebiotech
6d
Recon: FDA rejects ivonescimab for lung cancer indication; J&J to buy eye disease biotech Ollin Biosciences for up to $3.3B
raps
9d
STAT+: Up and down the ladder: The latest comings and goings
stat
9d
STAT+: HHS plans funding for research into ibogaine for PTSD
stat
9d
STAT+: Pharmalittle: We’re reading about Lilly conflict questions, a DEA OK for a narcolepsy pill, and more
stat
9d
Biopharma pushes beyond GLP-1s, weight loss at ObesityWeek 2026
biospace
9d
STAT+: Oura’s acquisition of health tech startup raises conflict-of-interest questions for Eli Lilly, experts say
stat
9d
FDA warns Chinese API manufacturers for refusing records requests, quality oversight
raps
9d
This Week: Senate HELP to vote on Overton, FDA shelves CNPV, and more
raps
10d
Deep dive: Cardiovascular calamities and catalysts
biospace
10d
Blackstone bets $1.5B on Pfizer’s obesity drug
biopharma dive
10d
STAT+: Pharmalittle: We’re reading about FDA shelving fast-track review, a Canadian importer arrested, and more
stat
10d
Pfizer snags $1.5B financing from PE firm Blackstone to support Metsera asset
biospace
10d
Blackstone commits up to $1.5B for R&D of Pfizer's ex-Metsera GLP-1
endpoints
← prev
page 1 of 16
next →